Publication | Open Access

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

Pembrolizumab Versus SunitinibUrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer TreatmentOpen-label StudyOncologyRadiation OncologyMolecular OncologyPhase 3